1. Home
  2. HCAT vs SABS Comparison

HCAT vs SABS Comparison

Compare HCAT & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Health Catalyst Inc

HCAT

Health Catalyst Inc

HOLD

Current Price

$2.46

Market Cap

162.0M

Sector

Technology

ML Signal

HOLD

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

HOLD

Current Price

$3.67

Market Cap

181.4M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HCAT
SABS
Founded
2008
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Programming Data Processing
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
162.0M
181.4M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
HCAT
SABS
Price
$2.46
$3.67
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$4.25
$9.80
AVG Volume (30 Days)
578.8K
311.5K
Earning Date
02-25-2026
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$316,063,000.00
$114,698.00
Revenue This Year
$3.23
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.63
N/A
52 Week Low
$2.02
$1.00
52 Week High
$7.25
$6.60

Technical Indicators

Market Signals
Indicator
HCAT
SABS
Relative Strength Index (RSI) 49.82 47.75
Support Level $2.23 $3.56
Resistance Level $2.42 $4.19
Average True Range (ATR) 0.12 0.22
MACD 0.02 -0.03
Stochastic Oscillator 77.42 28.15

Price Performance

Historical Comparison
HCAT
SABS

About HCAT Health Catalyst Inc

Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical stage biopharmaceutical company focused on the development and commercialization of a portfolio of products from its proprietary immunotherapy platform to produce fully targeted human polyclonal antibodies, without using human plasma or serum. The company's novel DiversitAb platform enables the rapid production of large amounts of targeted human polyclonal antibodies, leveraging transchromosomic cattle (Tc Bovine) that have been genetically designed to produce human antibodies (immunoglobulin G) rather than bovine in response to an antigen. Animal antibodies have been made in rabbits, sheep and horses.

Share on Social Networks: